

Milan, July 30, 2015

# The principles of frequentist and Bayesian medical statistics

Paolo Bruzzi

Clinical Epidemiology Unit

National Cancer Research Institute

Genova - Italy

# Statistical Mantra

- A study must have an adequate size
  - To warrant an adequate “power” to the study (i.e. to reduce the risk of a false negative result  
false negative: an effective treatment is not recognised)
  - To obtain precise estimates of the effects of the experimental therapy

# Conventional Statistical Rules

- *A study must have an adequate size*
- Required Size, based on:
  - Significance level (usually 5%)
  - Power (usually 80-90%)
  - Minimal clinically worthwhile difference

# Sample Size in cancer clinical trials

In trials in early disease, cumulative mortality  
from 10% to 70%: **500-5000** pts

In trials in advanced disease, cumulative  
mortality from 50% to 90%: **300-1000** pts

# Conventional Statistical Rules

- *A study must have an adequate size*
- *Required Size: Usually Hundreds/Thousands of patients*
- In many rare cancer conditions: **NOT POSSIBLE**
  - Incidence
  - Age
  - Molecular variant
  - Stage

# Statistical Mantra

- A study must have an adequate size

## Unjustified Implication

- If an adequate size cannot be attained, (RARE CANCERS) no methodological ties

Small size → Poor quality

# Poor Quality?

- (Study protocol)
- (Classified as Phase II trials)
- No Randomised controls
- Opaque selection of cases
- Primary endpoint: Objective response
- No statistical plan

# First point to stress

The organization of a trial of small size requires more care in

- Protocol preparation
- Study design/methodology
- Statistical design
- Addressing Clinical Organizational issues

...than a standard size trial

# Methodological issues

- *Statistical Power*
- Study Design
- Bias in evaluating outcome (double blind)
- Endpoint

VALIDITY!

# Study Design

- Uncontrolled trial/Historical Controls
  - Well Kown Biases
  - Sufficient if outstanding benefit
  - Necessary if control group unethical

Careful and transparent methodology

Need of guidelines/research

# Study Design

- *Uncontrolled trial/Historical controls*
- Randomised Controls

WHY NOT?

# RCT's in rare cancers

## Pro's

- **VALIDITY**
- **CREDIBILITY**

## Con's

- Moderate loss in power
- Often no standard (untreated control group?)
  - Ethics?
  - Acceptance?

# Trials in Rare Cancers

If, despite International cooperation/Prolonged accrual

- it is possible to assemble (in a reasonable time) only a limited number of patients,
- and the efficacy of a new treatment is not outstanding ...

# What can be done?

## Recent developments

- Bayesian Statistics
- Surrogate endpoints
- New types of systematic reviews
- Adaptive trials

# Common beliefs

## Frequentist probability

- Objective
- «Hard»
- Useful to analyse experiments
- Scientific

## Bayesian Probability

- Subjective
- «Soft»
- Inappropriate to analyse experiments
- Not scientific

**WRONG**

# Differences between Conventional (Frequentist) and Bayesian Statistics

- Meaning of probability
- Use of prior evidence

# Frequentist Probability

Probability of an observation

(given a hypothesis)

# Bayesian Probability

Probability that a hypothesis is true

(given observation and prior knowledge)

# Frequentist Probability

Probability of the observed difference (if the experimental therapy does not work)

# Bayesian Probability

Probability that the experimental therapy works/doesn't work (given observed difference and prior knowledge)

# Frequentist Probability

Definitions and implications

# Probability

Definitions (Wikipedia, from Merriam Webster)

...the measure of the likeliness that an event will occur

*Probability = measure of the  
likeliness that an event will occur?*

- Probability that next number from a roulette will be red =  $18/37 \approx 50\%$
- Probability that a man has a cancer in his prostate  $\approx 25/100 = 25\%$
- Probability that my home team (Genoa) had won last game =  $<1/\text{million} \approx 0$

*Probability = measure of the  
likeliness that an event will occur?*

- Probability that next number will be red
- Next Number: red = event
- Likelihood =  $18/37 \approx 50\%$

Theory:

Red Numbers / Total Numbers = Proportion

Experiment

Red Numbers/Plays = Frequency

*Probability = measure of the  
likeliness that an event will occur?*

Probability of an event = proportion

Estimation = frequency = events/plays

Probability = *measure of the likelihood that an event will occur?*

- *Probability that next number from a roulette will be red =  $18/37 \approx 50\%$*
- Probability that a man has a cancer in his prostate  $\approx 25/100 = 25\%$ 
  - Proportion: 25 prost.c./100 adult men
  - Estimation: Frequency of examined men in whom I do find a prostate c.:  
1 every 4 men (25%)

Probability = *measure of the likelihood that an event will occur?*

- *Probability that next number from a roulette will be red =  $18/37 \approx 50\%$*
- *Probability that a man has a cancer in his prostate  $\approx 25/100 = 25\%$*
- Probability that my home football team (Genoa) had won last game =  $<1/\text{million} \approx 0$

Proportion? Frequency?

*Probability = measure of the  
likeliness that an event will occur?*

- If my home football team (Genoa) could play again the last game a million times it would not win once

- Theoretical Proportion
  - Theoretical Frequency
- = Hypothesis

*Probability = measure of the  
likeliness that an event will occur?*

- Probability that next number from a roulette  
will be red =  $18/37 \approx 50\%$

IF (Hypothesis)...

...the roulette works fine  
(TRUE Frequency = 50%)

# Probability = *measure of the likelihood that an event will occur?*

- *Probability that next number from a roulette will be red =  $18/37 \approx 50\%$*
- Probability that a man has a cancer in his prostate  $\approx 25/100 = 25\%$

IF (Hypothesis)...the true prevalence of prostate cancer in Western adult men is 25%

# Probability = *measure of the likelihood that an event occurs?*

- *Probability that next number from a roulette will be red =  $18/37 \approx 50\%$*
- *Probability that man has a cancer in his prostate  $\approx 25/100 = 25\%$*
- Probability that my home football team (Genoa) had won last game =  $<1/\text{million} \approx 0$   
IF (Hypothesis)... Genoa does not change his players


# FREQUENTIST PROBABILITY

The expected frequency

of the observation

given a hypothesis (IF...)

# FREQUENTIST TEST OF HYPOTHESIS




compute

If it is not a rare event

The expected frequency

of the observation

Given a hypothesis (IF...)



REJECT  
THE  
HYPOT  
HESIS

If it is too rare

## Other examples of frequentist probabilities

- If the roulette works fine (reds = 50%):
  - Probability that next 3 numbers are red = 12.5%
  - Probability that 1/5 numbers are red = 19.2%
  - Probability that 1/10 numbers are red = 10%

# TESTS of HYPOTHESIS

- Does the roulette work fine (reds = 50%)?
  - Next 3 numbers are all red  $P=12\%$  ?

– 1/5 numbers are red  $P=19\%$  ?

– 1/10 numbers are red  $P = 1\%$  (2% if 2-sided)

Too rare: I reject the hypothesis that the roulette works fine

# This is what medical statistics is (was) all about!

1. Set a hypothesis (null hypothesis,  $H_0$  )
2. Do the study
3. Compute the probability (frequency,  $P$ ) of the observed results if  $H_0$  is true
4. If  $p$  is large, (usually  $>5\%$ ) do not reject
5. If  $p$  is small (usually  $<5\%$ ) reject  $H_0$

# Conventional Statistical Reasoning in Medicine

1. Starting Hypothesis = Null Hypothesis,  $H_0$ ):

New treatment = Standard (no treat.)

2. To demonstrate that new treatment is effective

$H_0$  must be rejected

3. To reject  $H_0$

Only the results of the trial can be used

-> Trials of large size

# Scientific Method in Medicine

Standard Therapy



Laboratory  
or trials in  
other diseases



New Standard?

# Scientific Method in Medicine

Standard Therapy



Laboratory  
or trials in  
other diseases



Clinical TRIAL

# Scientific Method in Medicine

Standard Therapy



Laboratory  
or cl. studies



H<sub>0</sub>: Exp. No better than  
standard

**Clinical TRIAL**

# Scientific Method in Medicine

Standard Therapy



Laboratory  
or cl. studies



H<sub>0</sub>?

**Clinical TRIAL**

H<sub>1</sub>: Exp better

New Standard Th.

# Scientific Method in Medicine

Standard Therapy




# Scientific Method in Medicine

Standard Therapy



# Scientific Method in Medicine

Standard Therapy



# Scientific Method in Medicine

Standard Therapy

If

$P < 5\%$


~~H0?~~

~~Laboratory  
or cl. studies~~

Clinical TRIAL


~~H1?~~

~~New Standard Th.~~



# Scientific Method in Medicine

Standard Therapy



# Scientific Method in Medicine

Standard Therapy




Laboratory  
or cl. studies



H0?

Clinical TRIAL

New Standard  
Therapy



# Advancement of knowledge in Medicine (conventional statistics)

- Dominant theory is true (=standard therapy is better) until sufficient evidence becomes available against it
- To this purpose, only evidence collected within one or more trials aimed at falsifying it can be used
- No use of
  - External evidence
  - Evidence in favor of...

# How to interpret the results of a study

- Internal Validity
- Biological Plausibility
- Internal Coherence
- External Consistency
  - Direct
  - Indirect

**Null Hypothesis (H0): the new drug is identical to the standard (if no standard, completely ineffective)**

- Biological Rationale
- Preclinical studies (disease models)
- Evidence of activity in Phase II
- Evidence of activity within same trial
- Efficacy in other diseases with similar.
- Efficacy in other stages same disease

# The 2 Reasons why large numbers of patients are needed in clinical trials

- Outstanding efficacy seldom observed
- Any knowledge outside the primary analysis of the clinical trial is ignored in the design and analysis of the trial

# Hypothetical Example

- As a statistician, I'm asked to design 2 separate trials in the same rare disease, squamous gastric cancer (no standard treat.)

- Study A:

Experimental therapy: Radiochemotherapy

- Effective in squamous cancers of other sites
- Phase II trial; Response Rate 60%

- Study B


- Experimental therapy: Intercessory prayer

# Squamous gastric cancer

Planning a trial of

RT+CTX

Analysing its results  
(p value)




# Squamous gastric cancer

Planning a trial of

RT+CTX

Intercessory prayer

Analysing its results  
(p value)



# Squamous gastric cancer

Planning a trial of

**Same Numbers,  
Same Statistical  
plan**

RT+CTX

Intercessory prayer

Analysing its results

(p value)

# Squamous gastric cancer

## Results of the 2 trials

RT+CTX



20% reduction  
in deaths  $P=0.15$



Intercessory prayer



20% reduction  
in deaths  $=0.15$



Treatment x next patient with SGC?

# Frequentist P

Probability of the observed difference if  
either therapy does not work = 15%

# Bayesian Probability

Probability that either therapy works a lot/  
works a little/does not work ?

Is it the same for the two treatments?

# Differences between Conventional and Bayesian Approaches

- *Meaning of probability*
- Use of prior evidence

# Conventional P

Probability of the observed difference (if the experimental therapy does not work)

# Bayesian Probability

Probability that the experimental therapy works/doesn't work (given observed difference and prior knowledge)

# Conventional (frequentist) statistical reasoning

Experimental evidence

# Bayesian statistical reasoning

Experimental evidence + Previous Knowledge

# Example

Mortality

**Tumor X**

**Nil vs A 15% vs 10%**

**N=2000**

**P = 0.0001**

**H0 Rejected: A is effective in X**

# Example

Mortality

*Tumor X Nil vs A 15% vs 10%*

*N=2000*

*P = 0.0001*

**Tumor Y Nil vs A 15% vs 7.5%**

**N= 240**

**P=0.066**

**H0 not rejected: A not shown effective in y**

# Prior Information:

X and Y are BRAF+

Mortality

*Tumor X*

*Nil vs A 15% vs 10%*

*N=2000*

*P = 0.0001*

Tumor Y

Nil vs A 15% vs 7.5%

N= 240

P=0.066

## Prior Information:

X and Y are BRAF+

A = Anti BRAF

Mortality

*Tumor X Nil vs A 15% vs 10%*

*N=2000*

*P = 0.0001*

Tumor Y

Nil vs A 15% vs 7.5%

N= 240

P=0.066

INTERPRETATION?

# Interpretation of the two trials

CONVENTIONAL

Tumor X:  $P = 0.0001$

Tumor Y :  $P = 0.066$

Efficacy of treatment A

proven in X

undemonstrated in Y

# Interpretation of the two trials

## *CONVENTIONAL*

*Efficacy of treatment A is proven in X,  
undemonstrated in Y*

## BAYESIAN

(Posterior) Probability that treatment A  
significantly (HR<0.8) lowers mortality

in tumor X: 90%

in tumor Y: 90%

# Disadvantages of Bayesian Statistics

- It is (felt as)
  - Subjective
  - Arbitrary
  - Amenable to manipulations  
(*pharma companies?*)

# Conceptual Advantages of Bayesian Statistics

- Reflects human reasoning (“common sense”)
- It is focused on estimates of effect
- Provides a conceptual framework for medical decision making
- IT IS TRANSPARENT

# Practical Advantages of Bayesian Statistics in rare tumors

1. No need to set the sample size in advance

Adaptive designs: enrol patients until sufficient evidence in favour or against efficacy

2. When strong a priori evidence is available and trial results are in agreement with it

**Smaller sample size is necessary – You can stop any time**

# Prior evidence in Bayesian statistics

Note: The difference between Bayesian and conventional statistics decreases with increasing strength of the empirical evidence

Rare Tumors!

# Prior evidence in Bayesian statistics

- Needed in order to compute posterior probability

# Prior evidence in Bayesian statistics

- *Needed in order to compute posterior probability*
- It must be transformed into a probability distribution (mean, median, standard deviation, percentiles, etc)

# Prior evidence in Bayesian statistics

- *Needed in order to compute posterior probability*
- *It must be transformed into a probability distribution*
- **Based on**
  - Objective information
  - Subjective beliefs
  - Both

# Prior evidence in Bayesian statistics

No special way to elicit/obtain prior information

No special way to summarize information


- Meta-analytic techniques

Frequentist - Bayesian

# Sources of prior evidence

- *Randomised Trials*
- Biological & Preclinical Studies
- Case-reports
- Uncontrolled studies
- Studies with surrogate endpoints
- Studies on other similar cancers
- Studies on the same cancer in different stages
- Others?

# Meta-analyses in frequent tumors

- *Randomised Trials*
  - Biological & Preclinical Studies
  - Case-reports
  - Uncontrolled studies
  - Studies with surrogate endpoints
  - Studies on other similar cancers
  - Studies on the same cancer in different stages
  - Others?
- 

# Meta-analyses in frequent tumors

- *Randomised Trials*

Weighted exclusively based on their size  
(and quality)

# Rare Tumors

~~- Randomised Trials~~

- Biological & Preclinical Studies
- Case-reports
- Uncontrolled studies
- Studies with surrogate endpoints
- Studies on other similar cancers
- Studies on the same cancer in different stages
- Others?

# Meta-analyses in rare tumors

Need to use information from studies

- <100% valid
- <100% pertinent to the question of interest
  - Different cancers
  - Different treatments
  - Different endpoints

# Prior evidence and clinical trials

Need to develop and validate new (meta-analytic) approaches to summarize prior information in rare tumors

## Requirements

- Explicit
- Quantitative
- Reproducible

# Efficacy trials in rare tumors

- Uncontrolled efficacy (phase III) trials of high quality
- Randomized activity (Phase II) trials followed by uncontrolled efficacy trials (with historical controls)
- RCT's with surrogate endpoints
- Adaptive, Bayesian, activity/efficacy RCT's based on unconventional Systematic Reviews



## RCT's in rare cancers

- Loss of power (50% less patients in exp treatment)

Available patients : 100

Cure Rate in controls: 40%

RCT (50 x2): 80% power for delta: 30% (to 70%)

Uncontr. trial 80% power for delta: 21% (to 61%)

# RCT's in rare cancers

- Loss of power /Precision  
(50% less patients in exp treatment)  
Available patients : 100

RCT (50 x2):                      Difference +/- 15%

Uncontrolled tr.                      Difference +/- 11%

(Histor. Controls)

# Differences between the present and the proposed approach

- Present :
  - Rational but informal integration of the available knowledge
- Proposed (Bayesian)
  - Formal, explicit and quantitative integration of the available knowledge
    - Verifiable quantitative methods
    - Sensitivity analyses
    - Focus on summary effect estimates